viernes, 13 de noviembre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 21, 2026

Radiation Dose Management Market Set for Strategic Growth, New Report Offers Critical Insights and Competitive Advantage | Astute Analytica

View original at finance.yahoo.com
Radiation Dose Management Market Set for Strategic Growth, New Report Offers Critical Insights and Competitive Advantage | Astute Analytica AstuteAnalytica India Pvt…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Hospitals dominate the radiation dose management market, capturing approximately 50% of the share

    80% confidence

  • Software platforms have helped reduce protocol deviation errors by as much as 52%

    80% confidence

  • United States and Germany together account for 45% of all AI-related patents in radiation dose management

    80% confidence

  • 78% of U.S. hospitals had deployed AI-powered dose management systems such as Bayer's Radimetrics and GE HealthCare's DoseWatch by 2024, reflecting a 25% increase in adoption since 2022

    80% confidence

  • 78% of U.S. hospitals have adopted AI-enabled dose monitoring software in response to the Joint Commission's 2024 imaging safety standards

    80% confidence

  • The global radiation dose management market was valued at US$ 764.2 million in 2024 and is projected to hit the market valuation of US$ 2,301.3 million by 2033 at a CAGR of 13.03% during the forecast period 2025–2033

    80% confidence

  • Medic Vision's FDA-cleared AI platform reduces fluoroscopy time during cardiac procedures by up to 30%

    80% confidence

  • CT and MRI scans have increased by an average of 12% annually since 2020

    80% confidence

  • 68% of U.S. hospitals operate two or more CT scanners

    80% confidence

  • 92% of hospitals accredited by the Joint Commission utilize automated dose tracking systems to adhere to the 2024 update of TJC Standard PC.01.03.01

    80% confidence

  • By 2024, approximately 65% of U.S. hospitals had deployed advanced dose management solutions like Bayer's Radimetrics or GE HealthCare's DoseWatch

    80% confidence

  • Cardiac CT scans used for coronary artery screenings in Europe have surged by 25% between 2022 and 2024

    80% confidence

  • The software segment holds a commanding 70% share of the radiation dose management market

    80% confidence

  • United States accounts for approximately 75% of North America's radiation dose management market activity

    80% confidence

  • Only 53% of outpatient centers have adopted automated dose tracking technologies

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,995
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,995 hechos verificados con la fuente5,577 documentos fuente archivados
Consulta estos datos → isubstrate.com
Radiation Dose Management Market Set for Strategic Growth, New Report Offers Critical Insights and Competitive Advantage | Astute Analytica — Source | Via News | es.VIA.NEWS